ADA 2019: Real-World Study Shows Abbott's FreeStyle Libre CGM Reduced HbA1c Levels In Type 2 Diabetics
Executive Summary
At this year's annual American Diabetes Association (ADA) conference, Abbott presented real-world data from its FreeStyle Libre CGM suggesting it reduces HbA1c in type 2 diabetics. Look for more ADA coverage this week.
You may also be interested in...
Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott
Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.
Continuous Glucose Monitor From Senseonics Earns FDA Approval For ‘Non-Adjunctive’ Claim
Senseonics now can promote its Eversense continuous glucose monitoring system as a replacement for fingerstick testing to help patients make diabetes treatment decisions during the day, following FDA approval of a new non-adjunctive indication.
Continuous Glucose Monitor From Senseonics Earns FDA Approval For ‘Non-Adjunctive’ Claim
Senseonics now can promote its Eversense continuous glucose monitoring system as a replacement for fingerstick testing to help patients make diabetes treatment decisions during the day, following FDA approval of a new non-adjunctive indication.